Profusa's Groundbreaking Lumee PAD Trial Update Set to Shine at PVI 2025
The Future of Medical Monitoring
In the ever-evolving world of digital health, Profusa, Inc. stands at the forefront, pioneering innovative solutions that could revolutionize patient care. As thousands of healthcare professionals gear up for the Paris Vascular Insights (PVI) 2025 conference, all eyes will be on Profusa’s latest update on their U.S. Lumee PAD trial.
A Leap in Tissue Oxygen Monitoring
With the acceptance of their Late Breaking Clinical Trial Update, Profusa is set to showcase their Lumee™ Oxygen tissue monitoring platform at PVI 2025. This novel implantable hydrogel sensor is specifically designed to monitor tissue oxygen dynamics in patients with Peripheral Arterial Disease (PAD). According to Ben Hwang, Ph.D., Profusa’s visionary Chairman and CEO, “Our Lumee technology promises continuous, real-time insights into tissue oxygen levels within the body—a first-of-its-kind platform poised to transform both clinical and home patient care.”
Connecting Innovation with Expertise
The insights into this groundbreaking study will be delivered by none other than Peter Schneider, M.D., a revered Professor of Surgery at the University of California, San Francisco. Attendees can anticipate an immersive session held at the iconic Carrousel du Louvre on December 13, 2025. Schneider’s presentation promises to delve deep into the intricacies of using transcutaneous partial pressure of oxygen (tcpO₂) monitoring in PAD patients, highlighting Profusa’s commitment to practical, reliable medical innovation.
Profusa’s Vision for a Healthier Tomorrow
Based in Berkeley, California, Profusa’s journey is led by a team of visionaries and seasoned professionals committed to developing next-generation biosensors. Their tissue-integrated sensors are not only innovative but are designed to be long-lasting and accessible, ensuring medical-grade data that clinicians can trust will constantly flow for both personal and professional use.
A Prelude to the Future
The significance of this trial at PVI goes beyond mere academic interest; it signals a promising future where medical monitoring devices become seamlessly integrated with daily healthcare routines. Attendees at PVI 2025 will not only witness a pivotal moment in vascular and endovascular surgery advancements but will also partake in reshaping patient-centered care. As stated in the Stock Titan, such innovations are crucial in the continued push to enhance the quality and efficacy of medical treatments.
As Profusa steps into the global spotlight at PVI 2025, their efforts signal a bold stride toward a future where continuous biochemical monitoring could redefine healthcare as we know it.
